Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(16):1104-1105; doi:10.1093/jnci/djj351
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bankhead, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bankhead, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

New Finasteride Trial Results Aim To Curb Controversy

Charles Bankhead

The first 10% of the full text of this article appears below.

Three years after publication of the history-making Prostate Cancer Prevention Trial (PCPT), the controversy that often overshadowed the positive results appears headed toward resolution.

The PCPT demonstrated that 7 years of prophylactic treatment with finasteride reduced the risk of prostate cancer by 6% (from 24.4% in the placebo group to 18.4% in the finasteride group). However, the results also revealed a statistically significant 1.3% absolute increase in the incidence of high-grade cancer (Gleason sum ≥ 7) in the finasteride patients.

The high-grade disease "issue" assumed a front-and-center position and dampened enthusiasm for the use of finasteride to prevent prostate cancer, acknowledged PCPT principal investigator Ian M. Thompson, M.D., professor and chair of urology at the University of Texas Health Sciences Center in San Antonio. Little evidence exists to indicate that physicians are prescribing a 5{alpha}-reductase inhibitor . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?